CTI BioPharma to Present at the Cowen 41st Annual Health Care Conference on Thursday, Mar. 4
CTI BioPharma Corp. (NASDAQ: CTIC) will present a corporate overview at the Cowen 41st Annual Health Care Conference on March 4, 2021, at 12:10 p.m. EST.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CTI BioPharma Corp. (NASDAQ: CTIC) will present a corporate overview at the Cowen 41st Annual Health Care Conference on March 4, 2021, at 12:10 p.m. EST. This virtual event will be available for live webcast and replay on their website. The company focuses on developing targeted therapies for blood-related cancers, particularly myelofibrosis, and is also exploring treatments for COVID-19. The presentation will provide insights into CTI BioPharma's ongoing projects and strategic direction.
Details
News Market Reaction – CTIC
The recorded move for CTIC in the trading session of this news was +2.83%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, Feb. 25, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Cowen 41st Annual Health Care Conference at 12:10 p.m. EST. The conference will be held in a virtual meeting format.
Presentation details:
Event: Cowen 41st Annual Health Care Conference
Date: Thursday, Mar. 4, 2021
Time: 12:10 p.m. EST
The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.
About CTI BioPharma Corp.
We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.
CTI BioPharma Investor Contacts:
Maeve Conneighton/Maghan Meyers
+212-600-1902
View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-the-cowen-41st-annual-health-care-conference-on-thursday-mar-4-301235382.html
SOURCE CTI BioPharma Corp.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.